BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Newcastle Hospitals Clinical Skills Academy - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Newcastle Hospitals Clinical Skills Academy
X-ORIGINAL-URL:https://skillsacademy.newcastle-hospitals.nhs.uk
X-WR-CALDESC:Events for Newcastle Hospitals Clinical Skills Academy
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20241112T093000
DTEND;TZID=Europe/London:20241112T123000
DTSTAMP:20260419T134903
CREATED:20240614T122918Z
LAST-MODIFIED:20250429T144450Z
UID:10000076-1731403800-1731414600@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Introduction to Precision Cancer Medicine – November 2024
DESCRIPTION:The fundamental idea of precision medicine is to offer each cancer patient a treatment approach that is tailored to the unique biology and genetics of their disease. \nThis two session course provides an understanding of the concepts that underlie precision cancer medicine and both its promise and limitations. \nDr Elaine Vickers – a leading independent educator on the science of new cancer treatments – will explain how far we are able to use precision medicine by exploring the features of cancer we can target now\, and where we might get to in the future\, as well as looking at when precision medicine fails\, and why expectations and realities don’t always align. \nCourse delivery\nThe course comprises two morning sessions delivered online via Microsoft Teams: \nSession One\n\nTuesday 12 November 2024 9:30am – 12:30pm\nAn introduction to the scientific concepts that underpin the concept of precision medicine looking at the features of cancer cells that we can target\, the treatments available\, and the tests and technologies needed to match targets with treatments. Includes the example of non-squamous\, non-small cell lung cancer\, where a precision approach is often already used. \nSession Two \nTuesday 19 November 2024 9:30am – 12:30pm\nThe session focuses on the limitations and current realities of precision medicine. Elaine describes why a precision approach isn’t always possible\, or might not give the best outcome\, for every patient. \nThe session closes by exploring progress made in offering a precision-approach with three of the most common cancers: breast\, bowel\, and prostate\, and considering where we go from here. \nDelegates will be given access to recordings of all sessions for three months after completion of the course. If you are unable to attend a session the recording will ensure you can review any content you have missed. \nLearning outcomes\nBy the end of this introduction to precision cancer medicine delegates will: \n\nUnderstand what precision medicine means – the treatments we are currently working with\, what we can and can’t target and how immunotherapy fits in\nExplore the treatments we use in precision medicine – antibody-based treatments; small molecule kinase inhibitors; and immunotherapies\nRecognise testing methods and potential treatment targets – what we can test for and where to look\, testing for mutations and presence of proteins\, identifying patterns of mutations and what commercial testing platforms can tell us\nAppreciate whether or not we understand how to make a good match and why not everyone benefits from a precision-based approach\nGrasp some of the unsolved questions and limitations in precision medicine\nBe able to reflect on where we have got to\, and where we are heading\, with precision cancer medicine for lung\, breast\, bowel and prostate cancer.\n\nCourse lead\nDr Elaine Vickers PhD of Science Communicated Ltd\nDr Elaine Vickers\, PhD of Science Communicated Ltd has worked as a cancer educator for over twenty years and has previously acted as science communicator for three of the UK’s leading medical research charities\, including four years in the Science Information team at Cancer Research UK. \nElaine is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies and immunotherapies. \nShe is experienced in teaching people with any level of scientific or medical knowledge from cancer patients through to medical oncologists translating complex and often overwhelming topics into easily digestible and understandable knowledge\, using colourful illustrations to explain scientific concepts. \nHer book\, A Beginner’s Guide to Targeted Cancer Treatments\, was commended by the British Medical Association book awards. A second edition is due out in 2024. \nAudience\nThis content is ideal for research nurses\, clinical nurse specialists\, pharmacists\, and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with cancer\, including junior doctors. \nBooking\nTo book a place on this course go to Tickets at the bottom of the page. \nAt checkout you can make an online card payment or enter a coupon code to make alternative payment arrangements. \nAlternative payment arrangements include: \n\nrequesting an invoice (INVOICE)\,\nThe Newcastle upon Tyne Hospitals NHS Foundation Trust staff internal funding (NUTH) – you will need to complete a Trust study leave form.\n\nPlease see the Making payments & Coupons sections of the Help and FAQs.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/introduction-to-precision-cancer-medicine-november-2024/
LOCATION:Virtual delivery via MS Teams
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/10/MicrosoftTeams-image-1.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20241108T081500
DTEND;TZID=Europe/London:20241108T161500
DTSTAMP:20260419T134903
CREATED:20240819T123152Z
LAST-MODIFIED:20240819T123152Z
UID:10000087-1731053700-1731082500@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Improving clinical practice in Congenital Heart Disease (CHD) - November 2024
DESCRIPTION:Fetal\, paediatric and adult congenital cardiology is a rapidly developing field of medicine and as the network’s regional Level 1 Centre our experts are proud to offer a five-day course culminating in the provision of a Certificate of Achievement in Improving Clinical Practice in Congenital Heart Disease (CHD). \nThis 5 day course starting on Friday 8th November 2024 followed by four further sessions on consecutive Fridays until Friday 6th December 2024 provides a quality assured qualification and is appropriate for a range of healthcare professionals involved in the care of patients with congenital heart disease. \nThis course is delivered online via MS Teams. \nIt aims to provide learners with the knowledge and skills necessary to manage the care of a patient with congenital heart disease throughout their lifetime\, allowing healthcare professionals to develop vital skills and knowledge to manage the care of patients with complex anatomy and physiology. \nLearning outcomes\nThe aim of the course is to provide learners with the knowledge and skills necessary to manage the care of a patient with congenital heart disease (CHD) across the lifespan. \nAt the end of the course delegates will be able to: \n\nUnderstand the physiology of the normal heart and developing fetus in utero alongside the anatomy and physiology of common basic CHD lesions\nRecognise the complexities and pathway for diagnostic fetal imaging\, interventional cardiology\, the expected outcomes and approach to counselling\nRecognise normal ECG and common arrhythmias in CHD and the range of cardiac imaging approaches in the diagnosis and ongoing management including staged surgical options\nUnderstand the pathophysiology of pulmonary hypertension with associated CHD\nGain knowledge of the process of transportation and the importance of preparation and communication\nGain knowledge of pre-operative and post-operative care\, exploring complexities and challenges of managing the child with CHD\nUnderstand the common pharmacological strategies and complex nutritional requirements throughout a CHD patient’s life\nGain knowledge and understanding of advance\, complex pathways for transplantation\, extracorporeal life support and fontan surveillance\nNavigate ethical dilemmas and difficult and challenging conversations\, transition into adult services\, the psychological impact on health and wellbeing for the patient and their family and end of life care.\n\nCourse Lead\nKaye Walsh is Lead Nurse for the North East North Cumbria Congenital Heart Disease Network (NENC CHDN) with over 20 years’ experience in the field of paediatric nursing\, specifically in cardiology and cardiothoracic surgery having worked in specialist centres in Dublin and Newcastle as well as over 10 years of experience in clinical education. \nKaye is passionate about ensuring colleagues are supported to kept abreast of the very latest clinical practice and guidelines\, and is delighted to bring together an array of clinical experts in this field to share their knowledge with colleagues across our national CHD networks. \nAudience\nThis course is appropriate for range of healthcare professionals involved in the care of patients with congenital heart disease (CHD). \nCourse dates\n\n\n\n\nDate\nTopic\n\n\nFriday 8th November\nIntroduction to Congenital Heart Disease\n\n\nFriday 15th November\nMedical and surgical management pathways\n\n\nFriday 22nd November\nCo-existing conditions associated with Congenital Heart Disease\n\n\nFriday 29th November\nLiving with Congenital Heart Disease\n\n\nFriday 6th December\nPsychosocial care of the patient and their family\n\n\n\n\nFinancial information\nIf you are employed by Newcastle Hospitals NHS Foundation Trust\, you can use the coupon code NUTH at the checkout to make a provisional booking and you will need to arrange access to in-house development funding. Your booking will remain provisional until your request has been validated with a funding/study leave reference. \nIf you are not employed by Newcastle Hospitals and are to be funded by your employer you can pay using an online card or an invoice can be requested by using the coupon code Invoice. \nPlease see Coupons for further information relating to coupon codes and how to use them at checkout.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/improving-clinical-practice-in-congenital-heart-disease-chd-november-2024/
LOCATION:Virtual delivery via MS Teams
CATEGORIES:Improving Practice in Congenital Heart Disease (CHD)
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/05/Paediatric-SIM-Training-scaled.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20241022T093000
DTEND;TZID=Europe/London:20241022T123000
DTSTAMP:20260419T134903
CREATED:20240614T130156Z
LAST-MODIFIED:20250429T143126Z
UID:10000080-1729589400-1729600200@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Beginner's Guide to Cancer Immunotherapy - October 2024
DESCRIPTION:This course will introduce the science behind many forms of immunotherapy\, including immune checkpoint inhibitors\, treatment vaccines\, and CAR T cells. \nOverview\nAn introduction to immunotherapy: what it is\, how it works\, and who it’s given to. \nDuring this half day course Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – will introduce the science behind modern cancer immunotherapies for solid tumours and haematological cancers. \nThe course begins with an introduction to the relationship between cancer and the immune system. This relationship evolves with time\, and Elaine will describe how cancer cells evade and suppress white blood cells to stay alive. \nShe then explains how immune checkpoint inhibitors such as nivolumab and pembrolizumab hope to boost the cancer-fighting response from the person’s immune system. To do this\, she’ll discuss some of the critical features of T lymphocytes and why they’re the focus of these treatments. \nFinally\, in the third session of the morning\, Elaine will describe many other forms of immunotherapy given to cancer patients. These include treatment vaccines\, oncolytic viruses\, double-ended proteins called T cell engagers\, TIL (tumour-infiltrating lymphocyte) therapy\, and CAR T cells. She’ll explain briefly how they work and why they’re valuable treatments for some patients and not others. \nAudience\nThis content is ideal for research nurses\, clinical nurse specialists\, pharmacists\, and clinical trials coordinators. It may also interest other healthcare professionals wanting to improve their understanding of immunotherapy. \nThis course is ideal for anyone new to cancer immunotherapy and would like to understand how these treatments came about and how they work. \nAs ever\, Elaine will use colourful illustrations and jargon-free explanations to help learners gain a broad understanding of the concepts covered. \nCourse delivery\nThe course comprises a single morning comprising three sessions\, delivered online via Microsoft Teams\, focusing on the following: \n\nSession one: An introduction to cancer and the immune system\nSession two: Immune checkpoint inhibitors\nSession three: Other forms of immunotherapy\n\nDetailed Programme\n9:30am Session 1 – Cancer’s relationship with the immune system  \n•         A brief introduction to the human immune system \n•         How our cells talk to our immune system \n•         Our immune system’s role in protecting us from cancer \n•         How cancer’s relationship with the immune system changes over time \n•         The difference between “cancer friends” and “cancer foes” \n10:30am Session 2 – Immunotherapy with checkpoint inhibitors  \n•         An introduction to T lymphocytes (T cells) \n•         What T cells do and why our body needs to control them \n•         How T cells kill cancer cells and what sometimes stops them \n•         The mechanism of action of immune checkpoint inhibitors such as pembrolizumab\, nivolumab\, and ipilimumab \n11:30am Session 3 – Other forms of immunotherapy  \n•         An overview of different immunotherapy strategies\, such as: \n•         Antibody-based immunotherapies given to people with haematological cancer \n•         T cell engagers: double-ended proteins that connect cancer cells and T cells \n•         Vaccine-based treatments that alert the body to the presence of cancer cells \n•         Using living T cells to treat cancer \n12.30pm – close \nCourse lead\nDr Elaine Vickers PhD of Science Communicated Ltd\nDr Elaine Vickers\, PhD of Science Communicated Ltd has worked as a cancer educator for over twenty years and has previously acted as science communicator for three of the UK’s leading medical research charities\, including four years in the Science Information team at Cancer Research UK. \nElaine is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies and immunotherapies. \nShe is experienced in teaching people with any level of scientific or medical knowledge from cancer patients through to medical oncologists translating complex and often overwhelming topics into easily digestible and understandable knowledge\, using colourful illustrations to explain scientific concepts. \nThe second edition of her book\, A Beginner’s Guide to Targeted Cancer Treatments – commended by the British Medical Association book awards is due out by the end of 2024. \nBooking\nTo book a place on this course go to Tickets at the bottom of the page. \nAt checkout you can make an online card payment or enter a coupon code to make alternative payment arrangements. \nAlternative payment arrangements include: \n\nrequesting an invoice (INVOICE)\,\nThe Newcastle upon Tyne Hospitals NHS Foundation Trust staff internal funding (NUTH) – you will need to complete a Trust study leave form.\n\nPlease see the Making payments & Coupons sections of the Help and FAQs.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/beginners-guide-to-cancer-immunotherapy-october-2024/
LOCATION:Virtual delivery via MS Teams
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/10/MicrosoftTeams-image-1.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20241003T093000
DTEND;TZID=Europe/London:20241003T123000
DTSTAMP:20260419T134903
CREATED:20240614T100835Z
LAST-MODIFIED:20250429T144244Z
UID:10000081-1727947800-1727958600@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Novel Immunotherapies for Solid Tumours - October 2024
DESCRIPTION:Please note that this course has been moved to Wednesday 27th November 2024\, please follow Novel Immunotherapies for Solid Tumours – November 2024\n  \nAn introduction to progress made in developing novel immunotherapies for solid tumours (excluding immune checkpoint inhibitors). \nOverview\nThis course emphasises the progress made in developing novel immunotherapies for solid tumours\, such as CAR T cell therapy\, TCR-engineered T cell therapy\, tumour infiltrating lymphocytes\, T cell engagers\, and vaccine-based treatments. \nOver the course of one morning\, Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – discusses novel approaches that may have a future as standard treatments for solid tumours including features of solid tumours that provoke the immune system and those that allow cancer cells to survive and thrive. \nElaine will describe cancers where novel immunotherapies are being most intensively explored\, such as in the treatment of: \n\ncancers already known to be sensitive to immunotherapy\, such as melanoma skin cancer\ncancers where new treatments are desperately needed\, such as pancreatic cancer and glioblastoma\ncancers where a particularly promising target has been identified\, such as Claudin 18.2 in stomach cancer and other GI cancers.\n\nIn the second session of the morning\, Elaine focuses on cell-based immunotherapies such as TIL (tumour infiltrating lymphocyte) therapy\, CAR T cell therapy\, and TCR-engineered T cell therapy. She explains why we haven’t made more progress with these treatments and explores how this might change in the future. \nIn the final session\, Elaine will examine some of the most innovative and exciting immunotherapies being developed\, including T cell engagers and mRNA vaccines. \nAudience\nThis content is ideal for research nurses\, clinical nurse specialists\, pharmacists\, and clinical trials coordinators. It may also interest other healthcare professionals wanting to improve their understanding of immunotherapy. \nAttendance on Elaine’s other course: A Beginner’s Guide to Cancer Immunotherapy would be ideal preparation for this course. \nAs ever\, Elaine will use colourful illustrations and jargon-free explanations to help learners gain a broad understanding of the concepts covered. \nCourse delivery\nThe course is delivered online via Microsoft Teams as follows: \n9.30am – Introduction to novel immunotherapies for solid tumours \n\nThe cancer-immunity cycle\nWhy not every cancer is sensitive to immunotherapy; exploring ‘Hot’\, ‘Cold’\, ‘Immune-suppressed’ and ‘Immune-excluded’ cancers\nHow cancer’s relationship with the immune system differs in different cancer types and the mechanisms that drive this\nIntroducing the cancers in which novel immunotherapies are being explored\n\nQ&A/break \n10.30am – Progress in cell-based immunotherapy for solid tumours \n\nWhere it started: TIL (tumour infiltrating lymphocyte) therapy\nIntroduction to CAR T cell therapy\nCAR proteins and their targets\nWhy don’t we have CAR T cell therapies for solid tumours?\nAn alternative approach: TCR-engineered T cells\n\nQ&A/break \n11.30am – Treatment vaccines\, T cell engagers and other novel approaches in trials \n\nVaccine-based immunotherapy – the general idea and the multitude of approaches being investigated\nPromising results from mRNA vaccine trials\nTebentafusp and tarlatamab – the first T cell engagers approved for solid tumours\nImmunotherapies that leverage macrophages and NK cells\n\nQ&A \n12.30pm – close \nCourse lead\nDr Elaine Vickers PhD of Science Communicated Ltd\nDr Elaine Vickers\, PhD of Science Communicated Ltd has worked as a cancer educator for over twenty years and has previously acted as science communicator for three of the UK’s leading medical research charities\, including four years in the Science Information team at Cancer Research UK. \nElaine is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies and immunotherapies. \nShe is experienced in teaching people with any level of scientific or medical knowledge from cancer patients through to medical oncologists translating complex and often overwhelming topics into easily digestible and understandable knowledge\, using colourful illustrations to explain scientific concepts. \nThe second edition of her book\, A Beginner’s Guide to Targeted Cancer Treatments – commended by the British Medical Association book awards – is due out by the end of 2024. \nBooking\nTo book a place on this course go to Tickets at the bottom of the page. \nAt checkout you can make an online card payment or enter a coupon code to make alternative payment arrangements. \nAlternative payment arrangements include: \n\nrequesting an invoice (INVOICE)\,\nThe Newcastle upon Tyne Hospitals NHS Foundation Trust staff internal funding (NUTH) – you will need to complete a Trust study leave form.\n\nPlease see the Making payments & Coupons sections of the Help and FAQs.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/novel-immunotherapies-for-solid-tumours-october-2024/
LOCATION:Virtual delivery via MS Teams
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/10/MicrosoftTeams-image.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20240905T093000
DTEND;TZID=Europe/London:20240905T123000
DTSTAMP:20260419T134903
CREATED:20240614T122313Z
LAST-MODIFIED:20250429T144128Z
UID:10000082-1725528600-1725539400@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Targeted Treatments and Immunotherapy for Solid Tumours: Demystifying the Science - September 2024
DESCRIPTION:Please note this course has been rearranged to start in February 2025.  Please follow the link for the course booking page: February 2025 course booking page\nThis course gives cancer nurses and trial staff the knowledge and confidence to discuss a wide range of targeted cancer treatments and immunotherapies with patients and colleagues. \nOverview\nThis course focuses on cancer biology and the science behind licensed treatments for solid tumours\, including monoclonal antibodies\, small molecule kinase inhibitors\, and immunotherapies. \nOver the course of two mornings\, Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – will guide you through the scientific concepts that underpin many of the most used targeted cancer treatments and immunotherapies for solid tumours. \nTreatments discussed include those that target cell communication pathways (e.g. EGFR and HER2-targeted treatments) and immune checkpoint inhibitors. Elaine also describes various molecular features of cancer that underpin many other new treatments. \nAudience\nThis content is ideal for research nurses\, clinical nurse specialists\, pharmacists\, and clinical trials coordinators. It may also interest other healthcare professionals wanting to improve their understanding of targeted treatments and immunotherapy. \nAs ever\, Elaine will use colourful illustrations and jargon-free explanations to help learners gain a broad understanding of the concepts covered. \nCourse delivery\nThe course comprises two mornings delivered online via Microsoft Teams as follows: \nSession One – Targeted cancer treatments\nOver three presentations\, Dr Vickers guides us through the scientific concepts underpinning many of the most used targeted cancer treatments. Beginning with the bigger picture – what we can and can’t target – she then describes the mechanisms of action of the two main types of treatment: monoclonal antibodies that target cell surface proteins and small molecules that block kinases. \nMany of these treatments target cell communication pathways. Elaine will explain the function of these pathways in healthy cells and their defects in cancer cells. She’ll also describe why blocking these pathways sometimes works and sometimes doesn’t. \nLastly\, Elaine turns her attention to other targets and discusses when a targeted therapy or immunotherapy approach is more likely to work. \nTargeted cancer treatments – the current landscape \n\nDescribing the ‘Enabling Characteristics’ that allow cancer to develop and the ‘Hallmarks of Cancer Cells’ that drive cancer’s behaviour\nWhich can we target\, and how can we do it?\nThe pros and cons of small molecule inhibitors and monoclonal antibodies\n\nTreatments that target cell communication \n\nTargeting growth factor receptors such as EGFR\, HER2\, and MET\nInhibitors of growth factor receptor fusion proteins: ALK\, ROS1\, RET\, TRKA/B/C\nB-Raf & MEK inhibitors for BRAF-mutated cancers\nThe pros and cons of PI3K & mTOR inhibitors\nProgress in targeting Ras proteins\n\nOther targets and treatments \n\nThe mechanism of action and limitations of angiogenesis inhibitors\nPARP inhibitors for cancers with defects in homologous recombination\nCDK inhibitors for hormone-sensitive breast cancer\nWhen is targeted therapy or immunotherapy the best strategy?\n\nSession 2: Cancer immunotherapy \nThe focus of this morning is on cancer’s relationship with the immune system and how this knowledge is being used to improve the outlook of people with various solid tumours. \nElaine describes how checkpoint inhibitors boost cancer-fighting T cells. She also highlights some of the lessons learned through the hundreds of clinical trials with checkpoint inhibitors that have taken place over the past decade. \nLastly\, Elaine explains how other forms of immunotherapy aim to create an anti-cancer immune response. \nAn introduction to immunotherapy \n\nA brief introduction to the immune system\nHow cancer’s relationship with the immune system changes over time\nHow the immune system can recognise and react to the presence of cancer in the body – the Cancer Immunity Cycle\nMechanisms of immune evasion by cancer cells\nAn overview of immunotherapy approaches and the importance of T cells\nReasons why immunotherapy sometimes does work and sometimes doesn’t\n\nImmunotherapy with checkpoint inhibitors \n\nIntroduction to checkpoint proteins on T cells\nDescribing the mechanism of action of checkpoint inhibitors\nSpot the difference: CTLA-4 and PD-1/P-L1 targeted checkpoint inhibitors\nSome of the many lessons learned from clinical trials with checkpoint inhibitors\n\nBiomarkers and combinations; other forms of immunotherapy \n\nDescribing the use of biomarkers to predict which patients will benefit from checkpoint inhibitors: what have we got and what’s coming?\nTreatment combinations to improve response rates\nNovel checkpoint inhibitors\nA broader look at immunotherapy strategies to create cancer-fighting T cells and the progress made in using them as treatments for solid tumours\nLooking to the future of immunotherapy for solid tumours\n\nDelegates will be given access to recordings of all sessions for three months after completion of the course. If you are unable to attend a session the recording will ensure you can review any content you have missed. \nCourse Lead\nDr Elaine Vickers PhD of Science Communicated Ltd\nDr Elaine Vickers\, PhD of Science Communicated Ltd has worked as a cancer educator for over twenty years and has previously acted as science communicator for three of the UK’s leading \nmedical research charities\, including four years in the Science Information team at Cancer Research UK. \nElaine is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies and immunotherapies. \nShe is experienced in teaching people with any level of scientific or medical knowledge from cancer patients through to medical oncologists translating complex and often overwhelming topics into easily digestible and understandable knowledge\, using colourful illustrations to explain scientific concepts. \nThe second edition of her book\, A Beginner’s Guide to Targeted Cancer Treatments – commended by the British Medical Association book awards is due out by the end of 2024. \nBooking\nTo book a place on this course go to Tickets at the bottom of the page. \nAt checkout you can make an online card payment or enter a coupon code to make alternative payment arrangements. \nAlternative payment arrangements include: \n\nrequesting an invoice (INVOICE)\,\nThe Newcastle upon Tyne Hospitals NHS Foundation Trust staff internal funding (NUTH) – you will need to complete a Trust study leave form.\n\nPlease see the Making payments & Coupons sections of the Help and FAQs.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/targeted-treatments-and-immunotherapy-for-solid-tumours-demystifying-the-science-september-2024/
LOCATION:Virtual delivery via MS Teams
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/10/Gene-therapy-for-cancer-concept-illustration-slim-for-course.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20240424T093000
DTEND;TZID=Europe/London:20240424T123000
DTSTAMP:20260419T134903
CREATED:20230929T072758Z
LAST-MODIFIED:20240319T111702Z
UID:10000048-1713951000-1713961800@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:The 4Ps Researcher Development Programme (April - September 2024) Cohort 5
DESCRIPTION:Attendance\nCohort 5 of the 4Ps Researcher Development Programme consists of the following sessions: \n\n\n\nSession\nDay\nDate\nTime\n\n\nFoundation\nWednesday\n24 April 2024\n9:30am – 12:30pm\n\n\nPlace\nThursday\n23 May 2024\n9:30am – 12:30pm\n\n\nProject\nTuesday\n18 June 2024\n1:00pm – 4:00pm\n\n\nPerson\nThursday\n11 July 2024\n9:30am – 12:30pm\n\n\nPlan\nWednesday\n18 September 2024\n9:30am – 12:30pm\n\n\n\nThese sessions will take place via Microsoft Teams. \nBooking\nTo book a place on this course go to Tickets at the bottom of the page. \nAt checkout you can make an online card payment or enter a coupon code to make alternative payment arrangements. \nAlternative payment arrangements include: \n\nrequesting an invoice (INVOICE)\,\norganisational arrangements for pre-payment (4Ps)\, and\nThe Newcastle upon Tyne Hospitals NHS Foundation Trust staff internal funding (NUTH).\n\nPlease see the Making payments & Coupons sections of the Help and FAQs. \nCourse details\nThe 4Ps Programme has been developed by Newcastle’s Nurses\, Midwives and Allied Health Professionals (NMAHPs) and designed to support your needs no matter where you are on the “research interested” to “Aspiring Clinical Academic” continuum. \nThis welcoming jargon-free modular programme has four modules: \n\nPlace\nProject\nPerson\nPlan\n\nThey provide you with the skills\, knowledge and confidence to move forward with research. \nThe starting point for the programme is our pre-requisite Foundation session . \nThe programme is delivered by a range of NMAHP clinical-academic colleagues\, and with input from relevant organisations including the Research Design Service\, Patient and Public Involvement panels\, universities and funders. \nWhat are the 4 Ps?\n\n\n  \nPlace\n“I am as nowhere as I can be\, can you add some somewhere to me?” \nThis module will help you to think about developing the right collaborations\, identifying the right expertise and choosing and engaging with mentors and supervisors who can support you on your journey. \nThis is such an important ingredient as relationships with mentors and supervisors can influence your whole career and can really help you to go places. \n  \n\nProject\n“Push harder than yesterday if you want a different tomorrow…” \nThis module will explore a recipe of key ingredients for a research project such as: \n\nlinking your work to strategic priorities\nlooking at the literature\ndeveloping your research question\nidentifying the right methodology and\nultimately starting to develop a project plan or application for funding.\n\n\n\n\nPerson\n\n“The best project you will ever work on is you…” \nThis module will help you to focus on you as an individual\, as a researcher and as a leader. \nWe’ll cover things like developing your research CV\, writing activities\, public speaking and all things confidence building for you as a researcher. \n  \n  \n\nPlan\n“It takes as much energy to wish as it does to plan.” \nPlanning is so important for any piece of research\, but it’s not just about planning the project. \nThis session will help you to think about the bigger picture\, influencing up\, down and across. \nAlso what to do next regardless of the outcome of a research related funding or fellowship application. \n  \nThe starting point for the course is the Foundation session. This is an essential building block which equips colleagues to go on to the subsequent modules. We learn about the research landscape\, and begin to think about where we fit into it. We cover topics like the difference between research\, audit and service evaluation. We spend time thinking about who we are as clinicians\, as potential researchers\, and what the opportunities might be for us. \nIntended Audience\nThe Newcastle Hospitals’ 4Ps Programme supports the needs of all NMAHPs regardless of where they are on their research journey. \n\n\n\n Add to calendar
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/the-4ps-research-development-programme-cohort-5-apr-sep-2024/
LOCATION:Virtual delivery via MS Teams
CATEGORIES:The 4 Ps Researcher Development Programme
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/09/4Ps-icon.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20240227T093000
DTEND;TZID=Europe/London:20240227T123000
DTSTAMP:20260419T134903
CREATED:20231005T230917Z
LAST-MODIFIED:20250429T144422Z
UID:10000059-1709026200-1709037000@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Introduction to precision cancer medicine - February 2024
DESCRIPTION:The fundamental idea of precision medicine is to offer each cancer patient a treatment approach that is tailored to the unique biology and genetics of their disease. \nThis two session course provides an understanding of the concepts that underlie precision cancer medicine and both its promise and limitations. \nDr Elaine Vickers – a leading independent educator on the science of new cancer treatments – will explain how far we are able to use precision medicine by exploring the features of cancer we can target now\, and where we might get to in the future\, as well as looking at when precision medicine fails\, and why expectations and realities don’t always align. \nCourse delivery\nThe course comprises two morning sessions delivered online via Microsoft Teams: \nSession One\n\nTuesday 27 February 2024 9:30am – 12:30pm\nAn introduction to the scientific concepts that underpin the concept of precision medicine looking at the features of cancer cells that we can target\, the treatments available\, and the tests and technologies needed to match targets with treatments. Includes the example of non-squamous\, non-small cell lung cancer\, where a precision approach is often already used. \nSession Two \nTuesday 5 March 2024 9:30am – 12:30pm\nThe session focuses on the limitations and current realities of precision medicine. Elaine describes why a precision approach isn’t always possible\, or might not give the best outcome\, for every patient. The session closes by exploring progress made in offering a precision-approach with three of the most common cancers: breast\, bowel\, and prostate\, and considering where we go from here. \nDelegates will be given access to recordings of all sessions for six months after completion of the course. If you are unable to attend a session the recording will ensure you can review any content you have missed. \nLearning outcomes\nBy the end of this introduction to precision cancer medicine delegates will: \n\nUnderstand what precision medicine means – the treatments we are currently working with\, what we can and can’t target and how immunotherapy fits in\nExplore the treatments we use in precision medicine – antibody-based treatments; small molecule kinase inhibitors; and immunotherapies\nRecognise testing methods and potential treatment targets – what we can test for and where to look\, testing for mutations and presence of proteins\, identifying patterns of mutations and what commercial testing platforms can tell us\nAppreciate whether or not we understand how to make a good match and why not everyone benefits from a precision-based approach\nGrasp some of the unsolved questions and limitations in precision medicine\nBe able to reflect on where we have got to\, and where we are heading\, with precision cancer medicine for lung\, breast\, bowel and prostate cancer.\n\nCourse lead\nDr Elaine Vickers PhD of Science Communicated Ltd\nDr Elaine Vickers\, PhD of Science Communicated Ltd has worked as a cancer educator for over twenty years and has previously acted as science communicator for three of the UK’s leading medical research charities\, including four years in the Science Information team at Cancer Research UK. \nElaine is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies and immunotherapies. \nShe is experienced in teaching people with any level of scientific or medical knowledge from cancer patients through to medical oncologists translating complex and often overwhelming topics into easily digestible and understandable knowledge\, using colourful illustrations to explain scientific concepts. \nHer book\, A Beginner’s Guide to Targeted Cancer Treatments\, was commended by the British Medical Association book awards. A second edition is due out in 2024. \nAudience\nThis content is ideal for research nurses\, clinical nurse specialists\, pharmacists\, and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with cancer\, including junior doctors. \nFinancial information\nIf you are employed by Newcastle Hospitals NHS Foundation Trust\, you can use the coupon code NUTH at the checkout to make a provisional booking and you will need to arrange access to in-house development funding. Your booking will remain provisional until your request has been validated with a funding/study leave reference. \nIf you are not employed by the Newcastle Hospitals an online card payment is required at the point of booking. \nAlternatively\, if you are to be funded by your employer an invoice can be requested by using the coupon code Invoice. \nPlease see Coupons for further information relating to coupon codes and how to use them at checkout.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/intro-precision-cancer-medicine-feb-2024/
LOCATION:Virtual delivery via MS Teams
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/10/MicrosoftTeams-image-1.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20231116T140000
DTEND;TZID=Europe/London:20231116T150000
DTSTAMP:20260419T134903
CREATED:20231004T105324Z
LAST-MODIFIED:20250429T144601Z
UID:10000057-1700143200-1700146800@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Introduction to cancer biology\, targeted and immunotherapies - November 2023
DESCRIPTION:This course introduces the biology of cancer\, the faulty genes that drive its behaviour\, and the science behind systemic treatments including immunotherapies and precision medicine. It also describes the rationale behind a diverse range of targeted drug treatments and immunotherapies available today. \nDr Elaine Vickers – a leading independent educator on the science of new cancer treatments – uses demystifying jargon to explaining the resistance mechanisms to many new treatments\, including the way cancer cells diversify and evolve and the complex environment in which they live. \nThis introductory course is ideal for healthcare professionals who are new to the provision of cancer care or wish to refresh their knowledge. \nCourse delivery\nThe course comprises a series of five\, one-hour long sessions delivered online via Microsoft Teams: \n\n\n\nSession\nTopic Date and Time\n\n\n      1\nCancer biology and genetics \nThursday 16 November 2023\n2:00 – 3:00pm\n\n\n      2\nTargeted cancer treatments \nThursday 23 November 2023\n2:00 – 3:00pm\n\n\n      3\nIntroduction to immunotherapy \nThursday 30 November 2023\n2:00 – 3:00pm\n\n\n      4\nImmunotherapy with checkpoint inhibitors \nThursday 7 December 2023\n2:00 – 3:00pm\n\n\n      5\nTargeted treatments and immunotherapies for haematological cancers \nThursday 14 December 2023\n2:00 – 3:00pm\n\n\n\nDelegates will be given access to recordings of all sessions for six months after completion of the course. If you are unable to attend a session the recording will ensure you can review any content you have missed. \nLearning outcomes\nBy the end of this introductory programme delegates will: \n\nUnderstand cancer as a disease caused by DNA damage that accumulates in individual cells combined with an ageing immune system\nBe introduced to targeted therapies – which patients receive them\, why they cause side effects and why they don’t always work\, as well as how they are designed and what they target\nExplore the relationship between cancer and the immune system and understand a range of immunotherapy approaches\, including the importance of T cells as a common immunotherapy target\nAppreciate the strengths and weaknesses of immune checkpoint inhibitors as an important group of immunotherapies now given to thousands of patients with many cancer types\nLearn about treatments for haematological cancers\, such as antibody-based treatments and small molecule kinase inhibitors\, including the progress made with CAR T cells.\n\nCourse lead\nDr Elaine Vickers PhD of Science Communicated Ltd\nDr Elaine Vickers\, PhD of Science Communicated Ltd has worked as a cancer educator for over twenty years and has previously acted as science communicator for three of the UK’s leading medical research charities\, including four years in the Science Information team at Cancer Research UK. \nElaine is experienced in teaching people with any level of scientific or medical knowledge from cancer patients through to medical oncologists translating complex and often overwhelming topics into easily digestible and understandable knowledge\, using colourful illustrations to explain scientific concepts. \nShe is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies and immunotherapies. \nHer book\, A Beginner’s Guide to Targeted Cancer Treatments\, was commended by the British Medical Association book awards. A second edition is due out in 2024. \nAudience\nThis course is ideal for nurses\, clinical trials staff or other healthcare professionals who are new to cancer care or would like to refresh their knowledge. \nFinancial information\nIf you are employed by Newcastle Hospitals NHS Foundation Trust\, you can use the coupon code NUTH at the checkout to make a provisional booking and you will need to arrange access to in-house development funding. Your booking will remain provisional until your request has been validated with a funding/study leave reference. \nIf you are not employed by the Newcastle Hospitals an online card payment is required at the point of booking. \nAlternatively\, if you are to be funded by your employer an invoice can be requested by using the coupon code Invoice. \nPlease see Coupons for further information relating to coupon codes and how to use them at checkout.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/introduction-to-cancer-biology-targeted-and-immunotherapies-november-2023/
LOCATION:Virtual delivery via MS Teams
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/10/Gene-therapy-for-cancer-concept-illustration-slim-for-course.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
END:VCALENDAR